BUZZ-Incyte up after European Commission expands use of cancer drug** Shares of drugmaker Incyte INCY.O rise 1.9% to $98.83
** Incyte says that the European Commission has approved its cancer drug Minjuvi in combination with lenalidomide and rituximab
** The new approval expands the use for the treatment of adult patients with relapsed or refractory follicular lymphoma after at least one line of systemic therapy
** FL is a type of cancer that begins in the lymph system, a part of the immune system
** Minjuvi was already approved by the EC in combination with lenalidomide for the treatment of relapsed or refractory diffuse large B-cell lymphoma
** Including session moves, stock up 42.2% YTD
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments